top of page

Milestones

Research and company milestones, from the first publications to today.

Research chronology

2019: Bench and human feasibility reports

2020: Ultrastructure and engineering publications

June 2021: DoD-funded randomized study (NCT04794621) begins at Indiana University

2022: Veterinary case reports published in Veterinary Surgery

July 2023: DoD-funded randomized study (NCT04794621) completed at Indiana University

September 2025: Murine preclinical study published in PLOS One

April 2026: Review article published in Frontiers in Microbiology

Building the company

September 2023: Pavaka Wound Care founded in Columbus, Ohio, by Brent Toto and Frank Fischer

October 2024: U.S. Patent 12,102,508 issued, “Antimicrobial Wound Care Dressing”

January 2025: Exclusive license from The Ohio State University announced

February 2025: Featured by The Ohio State University College of Engineering

April 2025: Ohio Third Frontier TVSF Phase 2 award ($200,000) from the Ohio Department of Development

July 2025: Graduated from Rev1 Concept to Customer, winning first place in the cohort peer vote

August 2025: Preliminary findings from the DoD-funded randomized study presented at MHSRS 2025

August–November 2025: Rev1 Customer to Capital accelerator, Fall 2025 cohort

November 2025: Rev1 Ventures Concept Contract funding ($150,000)

January 2026: Robert J. O’Connell, MD, joined as CMO & Director of Military Affairs

March 2026: Exhibited at OPMED 2026, San Antonio

April 2026: Wound Shark finalist, Wound Healing Society 2026 Annual Meeting at SAWC Spring (Charlotte)

June 2026: Two U.S. provisional patent applications filed on next-generation dressing designs

August 2026: Participated in MHSRS 2026 (Military Health System Research Symposium)

August 2026: USPTO Notice of Allowance for a second U.S. patent application

August 2026: Gen 2 dressing design completed with The Fischer Group under the Ohio TVSF grant; the six-volt Gen 2 configuration performed equivalently to Gen 1 in a laboratory agar assay at the University of Pittsburgh

​

What’s next

FDA pre-submission meeting for the Gen 2 dressing

510(k) submission for the three-volt Gen 2 configuration

De Novo pathway for the six-volt Gen 2 configuration, seeking a biofilm-related indication

First commercial focus: orthopedic and foot-and-ankle surgery

Plans are forward-looking and depend on FDA feedback and funding.

bottom of page